Page 11 - Pharma Sector News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The IT sector will likely remain stagnant in the next six months. However, if the US experiences a recession, both the IT and pharmaceutical sectors will be negatively impacted. The electronic manufacturing sector is expected to perform well in the near term. Mid and small-cap stocks are still in a good position, while the power sector and companies like REC and Power Finance are recommended for short-term tactical trades.

“In terms of numbers, if we are able to stay in that 18,900-20,400 kind of a band till Diwali, we would have done very well for ourselves. But I do believe at some point of time, we could test 18,900 and possibly even 18,400-18,500. On an overall basis, one should be aggressively booking profits in midcaps and smallcaps."

Rahul Singh of Tata Mutual Fund, emphasizes the importance of asset allocation and balanced portfolios in managing risks in the current market scenario. While global factors such as rising yields and the strengthening dollar index are impacting valuations, India's strong fundamentals and growth potential are expected to limit sharp corrections. Singh advises investors to focus on the right asset allocation and maintain a balanced portfolio.

It is not very common to see tailwinds emerging for an industry at a time when it is ideal to own stocks from that space. But in the case of pharmaceutical companies, tailwinds have emerged at a time when valuations of the overall market are expensive and it makes sense to look at pharma stocks as they tend to act as defensive stocks in volatile times with bearish bias. However they should not be clubbed together; each company has its own operating matrix. A company which has a strong domestic brand in the generic drugs segment, will not be getting impacted by what is happening in the US phar...

Glenmark Pharma has hived off a 75 percent stake in Glenmark Life Sciences, which accounted for nearly 11 percent of its consolidated top line, and had a 20 percent EBITDA contribution, to clear debt